Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (July 2024)
28 slides from Glucotrack's investor presentation, Jul 8, 2024
Slide 1: Advancing Diabetes Management
Glucotrack. Advancing Diabetes Management Next Generation Continuous Blood Glucose Monitoring July 2024
Slide 2: Important Disclaimers
Important Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: A Mission That Is Driven By People-Centric Values
A Mission That Is Driven By People-Centric Values Our mission is to push the boundaries of glucose sensor technology. Driven by people-centric design principles, our implantable Continuous Blood Glucose Monitoring (CBGM) technology establishes unmatched standards in accuracy, convenience, and indepe
Slide 4: Investment Highlights
Investment Highlights Significant Unmet @ Need & ped Commercial Opportunity Differentiated, Best-in-Class Technology + $9.8B global revenue in CGM in 2023, with strong growth in revenue and userbase; significantly underpenetrated'2 « Revolutionary CBGM utilizing advanced sensor technology + Leverage
Slide 5: Escalating Prevalence & Cost of Diabetes
Escalating Prevalence & Cost of Diabetes People Living with Diabetes (20-79 yrs.) Globally! Geography | 2021 2045 | increase us 32M 36M 13% Europe em 69M 13% ROW aaam [| 679M 53% Global Health Expenditure’ Diabetes-related increase in global health expenditure has grown from $2328 (2007) to $9668 (2
Slide 6: CGM Market - Global 2023 revenue of $9.8 Billion
CGM Market - Global 2023 revenue of $9.8 Billion’ Global Quarterly Revenue (millions) Key Launches & Milestones Driving Growth se0e 1999 In clinic CEMS (MARD 20's%) $2,500 $2,658 2006 1%t Home Use CGM launched 2012 iPhone connectivity $2,000 2014 Caregiver app functionality inate _— 2015 CGM MARDs o
Slide 7: Unaddressed Patient Needs Are A Catalyst for Future Growth
Unaddressed Patient Needs Are A Catalyst for Future Growth Longer sensor wear Aa% 64% Shorter sensor warmup time Sox 60% Smaller or thinner CGM sensor —_— ay 2018 y 2023 Better accuracy aad 34% . _ 21% Wider range or distance of transmission aon Better sensor adhesive a 20% Sewee Q6A G! 2018 Maker R
Slide 8: Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential
Introducing A Novel Approach to Managing Glucose with Best-in-Class Potential » Developed using best-in-class glucose monitoring and cardiac monitoring technology + Differentiated glucose monitoring technology which aims to combine the best of BEM & CGM Measures blood glucose vs interstitial fluid 1
Slide 9: Preclinical Data Shows Highly Accurate CBGM
Preclinical Data Shows Highly Accurate CBGM 250 %, @ R-IV (Line Fit), MARD = 3.4% = 200 oe @ L-IV (Line Fit, MARD = 3.6% SS e @BGM 7] 150 = 2 g o 100 J 2 Sanprgeasg © 50 0 -30 ie} 30 60 90 120 Excursion Time (Min) Glucotrack: 9 ©Copyright 2024. Al rig
Slide 10: Appealing Product Concept for Patients
Appealing Product Concept for Patients * Over 50% of respondents (N=757) are interested in the implantable CBGM concept. Current CGM users had the highest interest and likelihood to acquire, followed by CGM ex-users. Most Appealing Aspects Near Sensor fe 33%, Measures Blood Glucose I 25% No Wearable
Slide 11: Attractive Procedure Opportunity for Interventionalists
Attractive Procedure Opportunity for Interventionalists +» N=25 Interventional Cardiologists & N=25 Interventional Radiologists from 25 states; 40% of patients with diabetes. (on average) » 49 of 50 respondents would likely accept patient referrals from Endocrinologists to perform this procedure. 49
Slide 12: CBGM: Next Generation Innovation in Glucose Monitoring
CBGM: Next Generation Innovation in Glucose Monitoring ‘mum More Accurate Glucose Measurer + Measures blood, the gold standard for accuracy, with minimal lag time + Potential to advance standard of care for diabetes management (ability to automatically bolus with meal, not after, when incorporated i
Slide 13: Estimated US CBGM Opportunity
Estimated US CBGM Opportunity + Pre-2023, CGM market defined as: - T1D — T2D on intensive insulin therapy + Post-2023 CMS expansion, CGM market now includes: - T2D on basal insulin - T2D at hypoglycemia risk » CBGM has broad appeal for entire TAM - Current CGM users — Holdout CGM non-users — Dissati
Slide 14: Key Catalysts For Growth
Key Catalysts For Growth » Successful completion of first preclinical study - Assessed implant technique and confirmed device safety — Confirmed high level of accuracy - MARD of 8.1% at Day 30 and 4.5% at Day 60 + Initiation of long-term preclinical studies — Assessing sensor accuracy and longevity
Slide 15: Development and Regulatory Timeline
Development and Regulatory Timeline clini Animal FIM Chronic (N=20) resubmission Launch Regulatory a D> * +1 Year PMA Approval 2.Vear PMA Approval 15. © Copyright 2024, light reseed. cucorack Glucotrac!
Slide 16: Future Expansion Opportunity: Painful Diabetic Neuropathy
Future Expansion Opportunity: Painful Diabetic Neuropathy + Painful Diabetic Neuropathy (PDN) is a progressive neurological disorder that affects approx 1/5 of people with diabetes (> 7M individuals in the US)" — Symptoms include paresthesia, burning, and shooting pain Type of pain experienced by re
Slide 17: Epidural Glucose Monitoring for PDN Patients
Epidural Glucose Monitoring for PDN Patients + Spinal Cord Stimulation (SCS) technology recently FDA-approved as treatment option which provides significant long-term pain relief to PDN patients - SCS is the 2"4 most implanted technology in the US - Utilizes similar lead technology as cardiac pacema
Slide 18: Preclinical Epidural Chronic Study - Day Accuracy
Preclinical Epidural Chronic Study - Day 1 Accuracy © clucotrack © Commercial OGM Confirmed Pig-9175-d01 02-21, cutoff=2.00, MARD=4.38% 250.0 J 200.0 ° geo boe 2 eooneteeiee, Po e 0g eo e B 150.0 ma ° = e 2 os 8 100.0 “*brotogeegeceoSo® & [c} 50.0 0.0 -30 -10 10 30 50 70 90 Excursion Time (Min) 18 ©
Slide 19: Preclinical Epidural Chronic Study - Week Accuracy
Preclinical Epidural Chronic Study - Week 6 Accuracy Confirmed WEEK6 MARD 9.9% Glcuose (mg/dL) 8 3S } oe % e ? -30 -10 10 30 50 70 90 110 130 150 170 Excursion Time (Min) 19. © Copyright 2024. al sight
Slide 20: Our Advanced Glucose Sensor Technology Offers Multiple Opportunities for Success
Our Advanced Glucose Sensor Technology Offers Multiple Opportunities for Success CBGM Epidural Glucose Monitoring via + Interventional Cardiologist / SCS integration Radiologist Call Point & + Neurosurgeon Call Point & Reimbursement Pathway, Reimbursement Pathway - Target: Diabetes population + Targ
Slide 21: Proven Execution with Seasoned Leadership Team
Proven Execution with Seasoned Leadership Team Paul has many years developing innovative diabetes management technologies, including as VP of R&D at MetaCure, a neurostimulator device for Type 2 diabetes; Director of Engineering and Algorithm Development at Dexcom, a global continuous glucose monito
Slide 22: CBGM & Beyond: A Compelling Investment Opportunity
CBGM & Beyond: A Compelling Investment Opportunity Large Addressable Market & Favorable Macro Trends Commercial Opportunity Accelerating Adoption $9.88 global market for CGM in 2023, Diabetes is a significant global health Leveraging established with strong growth in revenue and concern, costing mor
Slide 23: Facts and Cap Table (as of July 5, 2024)
Facts and Cap Table (as of July 5, 2024) Exchange: Ticker NASDAQ: GCTK Headquarters Rutherford, NJ Invested to date ~ $75,000,000 Stock Price $1.74 52 Week Range $0.66 - $4.95 siucotrac, 23. ©Copyright 2024, All ights reserved
Slide 24: Appendix
APPENDIX G Glucotrack!
Slide 25: Company History Shows Willingness To Adapt to Market
Company History Shows Willingness To Adapt to Market 2001 2010 2013 2018 2021 2022 2023 Glucotrack.G
Slide 26: Experienced, Dedicated Board of Directors
Experienced, Dedicated Board of Directors ‘Mr. Malavé brings more than 20 years of leadership in the MedTech industry, primary in diabetes management. He has extensive expertise in product development, operations, matketin, strategic partnerships, and FDA regulatory strategy, Luis curently serves as
Slide 27: Glucose Monitoring Options Available Today
Glucose Monitoring Options Available Today Spot/Point-in-Time - measures a 7 eee eee Feast tnbioaleae Continuous ~ measures glucose in interstitial fluid every few ‘ pontine minutes for duration of sensor life single point in time Docineofianiactuats _ Smanufecurr «aatecurr Blood Interstitial Fluid
Slide 28: Thank You
Thank You 28 © Copyright 2024, Al rights reserved. Gucotrack